Asciminib is a medication being studied for its effectiveness in treating patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in the chronic phase. It is taken orally and works by specifically targeting and inhibiting a protein that is involved in the growth of cancer cells. The goal is to see if asciminib can help more patients achieve a significant reduction in cancer cell levels by Week 48 of treatment.

Investigator Selected TKI refers to a group of medications known as tyrosine kinase inhibitors (TKIs) that are chosen by the study investigators for comparison against asciminib. These medications are commonly used to treat chronic myelogenous leukemia by blocking the action of proteins that promote the growth of cancer cells. The study aims to compare the effectiveness of asciminib with these TKIs in achieving a major molecular response in patients.

Chronic Myeloid Leukemia – Chronic Myeloid Leukemia (CML) is a type of cancer that affects the blood and bone marrow. It is characterized by the overproduction of immature white blood cells, known as myeloid cells. These cells gradually accumulate in the blood and bone marrow, interfering with the production of normal blood cells. CML typically progresses through three phases: chronic, accelerated, and blast crisis, with each phase showing an increase in the number of abnormal cells. In the chronic phase, symptoms may be mild or absent, but as the disease progresses, symptoms such as fatigue, weight loss, and an enlarged spleen may occur. The disease is often associated with a specific genetic abnormality known as the Philadelphia chromosome.